Pfizer Vaccine May Protect Against UK Variant Of Coronavirus, Study Claims

Scientists have found evidence that the Covid-19 vaccine co-developed by the US pharmaceutical giant Pfizer and German biotechnology company BioNTech may protect against the novel coronavirus variant which originated in the UK and has been reported in several parts of the world, including India.

In a yet-to-be peer reviewed research, scientists from the University of Texas Medical Branch in the US, tested the ability of blood serum from 20 individuals immunised with the Pfizer-BioNTech vaccine to neutralise coronavirus engineered to carry the new mutations.

"Rapidly spreading variants of SARS-CoV-2 that have arisen in the UK and South Africa share the spike N501Y substitution, which is of particular concern because it is located in the viral receptor binding site for cell entry and increases binding to the receptor," the scientists noted in the study.

In these mutant forms, the molecule asparagine in the 501st position of the viral spike protein's amino acid sequence, is replaced by another amino acid tyrosine which is noted as Y.

"These rapidly spreading variants share the spike N501Y substitution. This mutation is of particular concern because it is located in the viral receptor binding site for cell entry, increases binding to the receptor, and enables the virus to expand its host range," the study noted.

When the researchers tested the sera of 20 participants who received the Pfizer-BioNTech vaccine they found that it could act against the engineered coronavirus variants.

"The new data provides important confirmation that the multiple antibodies generated against the spike protein (S) by vaccination remain able to inhibit cell entry by variant viruses," virologist Ian Jones from the University of Reading in the UK, who was unrelated to the study, said in a statement.

"This is because while some antibodies may not bind to S proteins with, for example the N501Y mutation, most antibodies still do, and this is sufficient to maintain protection," Jones added.

Gary McLean, Professor in Molecular Immunology from the London Metropolitan University in the UK said while the findings offer "good news", the study "did not construct SARS-CoV-2 with the full set of spike mutations in the UK variant and therefore further conclusions cannot be made fully at this stage."

While the current research, assessed the ability of the Pfizer-BioNTech vaccine to counter the strains carrying the N501Y mutation, virologist Lawrence Young from the University of Warwick in the UK said there are also other changes observed in these strains which might affect infectivity "and these have not been examined."

"This is particularly a concern with the South African variant which has accumulated two additional changes in the key receptor-binding domain of the spike gene," Young said.

"These changes are very likely to influence the infectiousness of this South African variant and may also impact its ability to be blocked by antibodies," he added.

Owing to the ongoing evolution of the coronavirus, scientists have called for the continuous monitoring of the significance of changes in the virus for vaccine coverage.

"This surveillance is accompanied by preparations for the possibility that a future mutation in SARS-CoV-2 might necessitate a vaccine strain change," the scientists wrote in the study.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.

We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor